

# ONX-0914

Catalog No: tcsc1625



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

960374-59-8

**Formula:**

$C_{31}H_{40}N_4O_7$

**Pathway:**

Metabolic Enzyme/Protease

**Target:**

Proteasome

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 35$  mg/mL (60.28 mM)

**Alternative Names:**

PR-957

**Observed Molecular Weight:**

580.67


## Product Description

ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

IC50 Value: ~10 nM [1]

in vitro: PR-957 blocked presentation of LMP7-specific, MHC-I-restricted antigens in vitro and in vivo. Selective inhibition of LMP7 by PR-957 blocked production of interleukin-23 (IL-23) by activated monocytes and interferon-gamma and IL-2 by T cells [1].

in vivo: In mouse models of rheumatoid arthritis and lupus, ONX-0914 treatment reverses signs of disease and results in reductions in cellular infiltration, cytokine production and autoantibody levels at well-tolerated doses. The maximum tolerated dose (MTD) of ONX-0914 in mice to be 30 mg/kg body weight. IFN-g release is inhibited by ~60% at LMP7-selective concentrations of ONX-0914 and by ~90% at higher concentrations. Production of IL-2 is also inhibited by ~50% [1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!